Detail akcie Zoetis Inc, Ordinary, New York Consolidated online

Business Summary: Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Financial Summary: BRIEF: For the three months ended 31 March 2025, Zoetis Inc revenues increased 1% to $2.22B. Net income increased 5% to $631M. Revenues reflect US segment increase of 2% to $1.18B, Contract Manufacturing segment increase of 45% to $29M, United States segment increase of 2% to $1.18B, Other emerging markets segment increase of 9% to $248M. Net income benefited from Foreign Exchange Gain/Loss decrease of 58% to $8M (expense).